SPRY · CIK 0001671858
What ARS Pharmaceuticals, Inc. told the SEC could break it.
ARS Pharmaceuticals is a single-product company — neffy is its only approved product, so its results depend almost entirely on that one launch — and the rest of its register is concentration around it. Sales flow through just a few distributors: four customers made up 79% of gross product sales in 2025, each between 15% and 22%. And it makes nothing itself, relying entirely on third-party contract manufacturers for all raw materials, drug substance and finished product, with the API and key components (Intravail and its nasal sprayer) sourced from suppliers in the European Union — which also leaves it exposed to potential EU and pharmaceutical import tariffs.
5 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- a handful of unnamed customers ~79% of gross product saleshigh
In FY2025 four customers made up 79% of gross product sales, each 15-22%; severe revenue concentration among a few wholesale/distributor customers.
“For the years ended December 31, 2025 and 2024 , four and six customers accounted for 79 % and 89 % of the Company's gross product sales, with each individual customer ranging from 15 % to 22 % and 11 % to 23 % of the Company'”
SEC filing →As of 2026
Other disclosures
- single-product dependence (neffy)high
neffy is the company's only approved product; results depend almost entirely on its commercialization.
“neffy is our only product that has been approved for sale.”
SEC filing →As of 2026
Geographic concentration
- API and key components sourced from EU suppliersmedium
Raw materials, API and key components (Intravail, nasal sprayer apparatus) for neffy are sourced from international suppliers located in the European Union.
“We source raw materials, active pharmaceutical ingredient (“API”) and other important components related to the manufacture of neffy and our intranasal epinephrine technology product candidates, including Intravail and our nasal sprayer apparatus, from international suppliers located in the European Union.”
SEC filing →As of 2026
Regulatory & policy
- EU / pharmaceutical import tariffsmedium
Tariff policies affecting the EU and pharmaceutical products could materially raise the cost of imported API and components.
“tariff policies, particularly those affecting the Europe Union and pharmaceutical products could materially increase”
SEC filing →As of 2026
Supplier concentration
- full dependence on third-party CMOs for all manufacturingmedium
ARS owns no manufacturing and depends entirely on third-party CMOs for all raw materials, drug substance and drug product.
“We currently depend on third-party contract manufacturing organizations (“CMOs”) for all of our required raw materials, drug substance and drug product for our preclinical research and clinical trials.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Alfresa Pharma Corporation
“the development and commercialization of neffy with Alfresa Pharma Corporation in Japan; Pediatrix Therapeutics, Inc. in China, Macau, Hong Kong and Taiwan; Seqirus in Australia and New Zealand; and ALK in all other unpartnered geographies outside the United States.”
Cited →ALK-Abelló A/S (ALK U.S.)
“the development and commercialization of neffy with Alfresa Pharma Corporation in Japan; Pediatrix Therapeutics, Inc. in China, Macau, Hong Kong and Taiwan; Seqirus in Australia and New Zealand; and ALK in all other unpartnered geographies outside the United States.”
Cited →Seqirus (CSL Limited)
“the development and commercialization of neffy with Alfresa Pharma Corporation in Japan; Pediatrix Therapeutics, Inc. in China, Macau, Hong Kong and Taiwan; Seqirus in Australia and New Zealand; and ALK in all other unpartnered geographies outside the United States.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch